Abstract
Cyclic peptides show diverse biological activities and are considered as good therapeutic agents due to structural rigidity, receptor selectivity and biochemical stability. We have developed bicyclic tetrapeptide HDAC inhibitors based on different cyclic tetrapeptide scaffolds. For the synthesis of these bicyclic tetrapeptides, two cyclization steps, namely, peptide cyclization and fusion of aliphatic side chains by ring closing metathesis (RCM) were involved. In the course of these syntheses, we have established two facts: a lower limit of aliphatic loop length and better synthetic route for bicyclic tetrapeptide synthesis. It was found that nine methylene loop length is the lower limit for aliphatic loop and the synthetic route selection depended on the configuration of amino acids in the cyclic tetrapeptide scaffold. RCM followed by peptide cyclization was the proper route for LDLD configuration and the reverse route was suitable for LLLD configuration.
Nine methylene units is the lower limit for aliphatic loop length and the synthetic route selection depends on the configuration of amino acids in the cyclic tetrapeptide scaffold. RCM followed by peptide cyclization is the proper route for LDLD configuration and reverse route for LLLD configuration.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Yokoyama F, Suzuki N, Haruki M, Nishi N, Oishi S, Fujii N, Utani A, Kleinman H K and Nomizu M 2004 Biochemistry 43 13590
Hruby V J 2001 Acc. Chem. Res. 34 389
Bolla M L, Azevedo E V, Smith J M, Taylor R E, Ranjit D K, Segall A M and McAlpine S R 2003 Org. Lett. 5 109
Humphrey J M and Chamberlin A R 1997 Chem. Rev. 97 2243
Joo S H 2012 Biomol. Ther. 20 19
Baeriswyl V and Heinis C 2013 Chem. Med. Chem. 8 377
Grubbs R H 2003 In Handbook of Metathesis (Weinheim, Germany: Wiley-VCH)
Grubbs R H 2006 Angew. Chem. Int. Ed. 45 3760
Schrodi Y and Pederson R L 2007 Aldrichimica Acta 40 45
Hoveyda A H and Zhugralin A R 2007 Nature 450 243
Prescher J A and Bertozzi C R 2005 Nat. Chem. Biol. 1 13
Miller S J, Blackwell H E and Grubbs R H 1996 J. Am. Chem. Soc. 118 9606
Ghalit N, Reichwein J F, Hilbers H W, Breukink E, Rijkers D T S and Liskamp R M J 2007 Chem. Bio. Chem. 8 1540
Berezowska I, Chung N N, Lemieux C, Wilkes B C and Schiller P W 2006 Acta Biochim. Pol. 53 (1) 73
Nishino N, Shivashimpi G M, Soni B, Bhuiyan M P I, Kato T, Maeda S, Nishino T G and Yoshida M 2008 Bioorg. Med. Chem. 16 437
Islam N M, Kato T, Nishino N, Kim H J, Ito A and Yoshida M 2010 Bioorg. Med. Chem. Lett. 20 997
Islam M N, Islam M S, Hoque M A, Kato T, Nishino N, Ito A and Yoshida M 2014 Bioorg. Med. Chem. 22 3862
Hoque M A, Islam M S, Islam M N, Kato T, Nishino N, Ito A and Yoshida M 2014 Amino Acids 46 2435
Komatsu Y, Tomizaki K, Tsukamoto M, Kato T, Nishino N, Sato S, Yamori T, Tsuruo T, Furumai R, Yoshida M, Horinouchi S and Hayashi H 2001 Cancer Res. 61 4459
Bierzyñski A 2001 Acta Biochim. Pol. 48 1091
Acknowledgement
This study was supported by Kitakyushu Foundation for the Advancement of Industry, Science and Technology (FAIS) and Japan Student Services Organization (JASSO).
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information
The electronic supplementary information (NMR spectra, figures S1-S5) is included which is available at www.ias.ac.in/chemsci.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
ISLAM, M.N., ISLAM, M.S., HOQUE, M.A. et al. Synthetic strategy for bicyclic tetrapeptides HDAC inhibitors using ring closing metathesis. J Chem Sci 127, 1563–1569 (2015). https://doi.org/10.1007/s12039-015-0922-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12039-015-0922-y